DailyIQ
Last updatedUpdating…

HSIC·Henry Schein, Inc.

$85.57
+0.54 (+0.64%)
After Hours
High
$86.25
Open
$85.19
Market Cap
9.40B
52W High
$92.18
Low
$84.56
P. Close
$85.57
P/E
23.32
52W Low
$60.30
Fwd P/E
14.19
DailyIQ Est.
$100.08
Inst. Ownership
48.4%
Short Interest
7.53%
Days to Cover
6.6
Technical Score (1D)
82
BULLISH
News Sentiment
56
BULLISH
With a Technical Score of 82, Henry Schein, Inc. (HSIC) sits in the upper tier of the momentum ranking on the 1D timeframe. The bullish bias and BUY signal follow from that rank, and trend strength reads as strong. Sentiment at 56 is aligned with the chart. Because the score is relative, it can stay high while the broader market falls, as long as HSIC holds up better than its peers. $81.63 is the near-term risk reference and $90.98 is the next upside marker if buyers keep pressing. DailyIQ's indicator breakdown shows how individual readings such as RSI (neutral range) and MACD (bearish) look right now. Those readings are context only and do not feed the Technical Score, which ranks HSIC's momentum against the rest of the universe.
LOW TARGET
$64 -25.2%
2 analysts
MEAN TARGET
$97 +13.7%
14 analysts
HIGH TARGET
$110 +28.6%
10 analysts
PRICE RANGE
$64.00 - $110.00
SB / B / H / S / SS
7/8/9/1/1
DAILYIQ EST.
$100.08 (+17.0%)
Sector
Healthcare
Industry
Medical Distribution
Exchange
NMS
Country
United States
Symbol
HSIC
Description
Henry Schein, Inc. is a global distributor of healthcare products and services, primarily catering to dental and medical practitioners. The company's core business revolves around providing a comprehensive suite of offerings, including dental merchandise, equipment, and pharmaceuticals, along with related services. Henry Schein also offers a range of specialty products, such as dental implants and biomaterials, differentiating itself through its broad product portfolio. Furthermore, the company supports its customers with practice management software and educational resources, solidifying its position as a value-added partner within the healthcare sector. Established in 1932, Henry Schein serves a diverse customer base, including private practices, laboratories, and institutional healthcare providers.
Bought (1Y)
0 shares
$0
Sold (1Y)
603 shares
$54K
Albertini AndreaCEO, Global Dist. & Tech.
D3,984 shares2026-09-08
Albertini AndreaCEO, Global Dist. & Tech.
Tax Withholding603 shares2026-09-08
DANIEL WILLIAM K-
Award/Grant2,215 shares2026-06-12
BERGMAN STANLEY M-
Gift50 shares2026-05-21
BERGMAN STANLEY M-
Gift1,040 shares2026-05-19
64/ 100
Neutral / mixed
Overall: Neutral
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
31.1%
Net Margin
3.0%
Revenue CAGR
4.4%
Current Ratio
1.38x
Debt / Equity
0.95x
Return on Equity
12.3%
Earnings Summary
Henry Schein, Inc. is a global distributor of healthcare products and services, primarily serving dental and medical practitioners with a broad portfolio that includes dental merchandise, equipment, pharmaceuticals, and practice management software. Operating within the medical distribution sector, the company leverages its long‑standing relationships with private practices, laboratories, and institutional providers to maintain a stable revenue base. In the most recent quarters, Henry Schein delivered revenue of $3.437 billion in Q4 2025 and $3.368 billion in Q1 2026, reflecting a modest year‑over‑year increase of roughly 2.5% in Q4 and a slight decline of 0.2% in Q1. EPS, however, showed a more pronounced trend: $1.34 in Q4 2025 versus $1.32 in Q1 2026, indicating a slight contraction of about 1.5% despite the revenue dip. The company beat analyst expectations in Q4 2025 (EPS $1.34 vs. $1.26 estimate) and in Q1 2026 (EPS $1.32 vs. $1.22 estimate), but missed in Q2 2025 (EPS $1.10 vs. $1.19 estimate) and Q3 2025 (EPS $1.38 vs. $1.28 estimate). Historically, Henry Schein has maintained a steady YoY revenue growth trajectory of around 3–4% over the past few years, with EPS growth lagging slightly behind due to margin pressures; the firm has consistently beaten revenue estimates while occasionally missing EPS forecasts. Recent news highlights the appointment of Emmanuel Caprais as CFO effective November 4, 2025, a move positioned to strengthen financial leadership and potentially enhance operational performance.

EPS

EstBeatMiss
$1.06$1.15$1.24$1.33$1.42Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.36 - -
Q2'26$1.26$1.27+0.7%
Q1'26$1.22$1.32+8.4%
Q4'25$1.26$1.34+6.3%
Q3'25$1.28$1.38+7.9%
Q2'25$1.19$1.10-7.6%

Revenue

EstBeatMiss
$3.2B$3.3B$3.4B$3.5B$3.6BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.5B - -
Q2'26$3.4B$3.5B+0.5%
Q1'26$3.4B$3.4B-0.2%
Q4'25$3.3B$3.4B+3.1%
Q3'25 - $3.3B -
Q2'25 - $3.2B -

Market Data

HSIC Stock Snapshot

BULLISH82/100
$85.56−$0.01 (0.0%)
Market cap
9.40B
P/E ratio
23.3
Day range
$84.56 – $86.25
News sentiment
56/100 · Neutral
Analyst target
$97.27 (+13.7%)
Consensus
Hold · 26 analysts
52-week range+41.9% off low · -7.2% from high
$60.30$92.18
Price $85.56 DailyIQ Est. $100.08

HSIC's technical picture is constructive, with trend and momentum pointing the same direction. Company-specific news dominates here; sector-level flows matter less than for larger names.

Reverse DCF

What growth is priced into HSIC?

FAIR

At today's price, Henry Schein, Inc. needs to grow free cash flow about 4.2% a year for the next 10 years to justify its valuation at a 7.45% cost of capital. Over its actual history it has compounded free cash flow at 2.6% a year, so the market is asking for 1.6 percentage points above its own delivered rate. On that basis HSIC looks priced roughly in line with its own growth record.

Implied FCF growth
4.2%
Historical FCF CAGR
2.6%
Growth gap
+1.6 pts
Verdict
FAIR
Discount rate (WACC)
7.45%
Beta
0.69

Behaviour On Record

What HSIC's own history says about today's numbers

Realized volatility (21d)
24.9% 63rd pct
Below its peak
-5.3%
vs 200-day average
+8.2%
Up days (1y)
52%

Henry Schein, Inc. is currently running 24.9% annualised volatility over the last 21 sessions. Measured against HSIC's own 13 years of daily returns rather than a market-wide average, that is the 63rd percentile — a little above its own norm, against a typical reading of 22.3%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

HSIC is trading -5.3% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -20.3%, and the deepest was -40.9% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +8.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 74th percentile — a somewhat wider gap than its own norm. Over the past year HSIC closed higher on 52% of sessions, and it is currently 4 sessions into a rising streak.

On October specifically: over 14 years of records, HSIC finished the month higher 6 of 14 times, with a median return of -1.6% and an average of -0.2%. Its strongest month historically has been November at +4.7% on average, its weakest August at -3.5%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: HSIC has opened more than 2% away from the prior close in 113 of 3,267 sessions (3.5% of the time), with the largest gaps running +5.2% and -10.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, HSIC moved an average of 1.6% in the session after earnings, closing higher 1 of those 3 times, with a median move of -1.7% and a largest of -2.6%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against HSIC's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of HSIC's sector?

Henry Schein, Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82

Options Market

What is the options market pricing for HSIC?

CallsPuts

For Henry Schein, Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.02), with at-the-money implied volatility around 87.9%. The options market is pricing roughly a ±6.6% move by that expiry — a range of about $81.38–$92.85.

Put/call ratio (2026-10-16)
0.02
ATM implied volatility
87.9%
Total open interest
1,155
Expected move by 2026-10-16
±6.6% ($81.38–$92.85)

Analyst Rating Changes

Are analysts turning bullish or bearish on HSIC?

BTIG most recently reiterated its rating on Henry Schein, Inc. to Buy on Aug 19, 2026 with a price target of $110 (from $100). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
BTIG — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Aug 19, 2026BTIGMaintainedBuy$100 → $110
Aug 6, 2026BarclaysMaintainedOverweight$86 → $100
Aug 5, 2026UBSMaintainedNeutral$89 → $94
Aug 5, 2026CitigroupMaintainedBuy$100 → $112
Aug 5, 2026BTIGReiteratedBuy$100
Jul 29, 2026Piper SandlerMaintainedOverweight$91 → $95
Jul 28, 2026UBSMaintainedNeutral$85 → $89
Jul 9, 2026BMO CapitalInitiatedMarket Perform$85
Jun 11, 2026BTIGUpgradeNeutral → Buy$100
May 6, 2026UBSMaintainedNeutral$87 → $85
May 6, 2026MizuhoMaintainedNeutral$88 → $82
Apr 24, 2026Morgan StanleyMaintainedUnderweight$61 → $64

Peers & ETF holders

HSIC peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

56/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Henry Schein announced Emmanuel Caprais would become its chief financial officer on November 4, succeeding Ronald South. Caprais, formerly CFO of ITT, will initially serve in an advisory capacity before fully assuming the CFO role. CEO Frederick Lowery praised Caprais for his proven financial leadership and ability to drive operational performance and profitable growth.
What did this article say?
Henry Schein (HSIC) announced that Emmanuel Caprais, previously CFO at ITT, will assume the CFO role effective November 4, joining the company as a senior financial adviser on October 12 to aid the transition. Ronald South, the current CFO, will shift to a senior advisory position on November 4.
What did this article say?
The article compares Henry Schein (HSIC) and Merit Medical (MMSI) as potential value picks in the medical‑dental supplies sector. Both companies hold a Zacks Rank of #2 (Buy) and have recently received positive earnings estimate revisions. The analysis highlights that HSIC’s valuation metrics—P/E, P/S, earnings yield, and cash flow per share—suggest it may be slightly undervalued relative to MMSI. No new earnings guidance or material corporate actions were disclosed, so the comparison remains a neutral assessment of current value positioning.
What did this article say?
Zacks Research noted that Henry Schein (HSIC) is currently attracting attention from value investors due to its favorable valuation metrics and high Zacks Rank. The firm highlighted HSIC’s placement in the “Value” category with an A‑grade, suggesting it may be undervalued relative to peers. No new earnings guidance, product launches, or regulatory changes were reported, so the outlook remains unchanged. The commentary focuses on HSIC’s positioning within the broader value investing strategy rather than on any specific catalyst. Overall, the piece presents a neutral assessment of HSIC’s current valuation status.
What did this article say?
On September 30, 2026, Henry Schein Inc. marked the 25th anniversary of its corporate citizenship program, Henry Schein Cares. The celebration highlighted the program’s five pillars—access, policy, relationships, team empowerment, and sustainability—illustrating the company’s commitment to health and community outcomes. The event underscored the program’s role in fostering collaboration among employees, customers, suppliers, and nonprofit partners. The milestone reinforced Henry Schein’s positioning as a leader in corporate responsibility within the healthcare supply sector.
What did this article say?
Henry Schein reported modest organic revenue growth of 2.9% year‑on‑year, below the sector average, indicating a potential slowdown in core demand. The company’s overall performance has lagged the broader market, with shares trailing the S&P 500 over the past six months. Analysts highlighted the risk of continued organic growth weakness and suggested investors consider alternative opportunities.
What did this article say?
Henry Schein amended and restated its revolving credit facility, raising total commitments to $1.25 billion and extending the termination date to September 19, 2031. The move was viewed as supportive of the company’s growth plans and risk profile, providing additional liquidity and flexibility for future investments.
What did this article say?
Henry Schein’s stock rose 30.7% over the past year, yet analysts question whether the company’s cash‑flow generation can justify the current price. The distributor’s valuation, based on free‑cash‑flow multiples, suggests the share price may be overstated relative to intrinsic value.
What did this article say?
Henry Schein (HSIC) was highlighted as a cash‑producing company that may not be a good investment. Analysts noted that the firm’s core business has underperformed, with organic revenue disappointing for two consecutive years and earnings growth lagging peers. Capital returns have been shrinking, suggesting that competition is eroding profitability. The company’s free cash flow margin of 4.2% and a forward P/E of 15x were cited as metrics that raise caution for investors.
What did this article say?
Henry Schein (HSIC) surpassed the Dow over the past year, according to a Yahoo report. Analysts noted the stock’s relative strength and expressed cautious optimism about its future trajectory. The outperformance suggests resilience amid broader market volatility. No material guidance changes or earnings surprises were reported. The article highlights the company’s solid positioning within the healthcare supply sector.

Technical Analysis

Real-time indicators across multiple timeframes

82
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $4.37B combined position · 12 adding, 13 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▼ Sell11,588,19910.48%$875.84M2026-01-29
FMR LLC (Fidelity)▲ Buy7,553,9016.83%$630.90M2026-08-13
BlackRock, Inc.▲ Buy7,024,6636.35%$586.70M2026-08-07
Artisan Partners Limited Partnership▼ Sell6,467,4675.85%$540.16M2026-08-13
JPMorgan Chase & Co▼ Sell4,342,9293.93%$366.43M2026-08-12
Invesco Ltd.▼ Sell3,150,2372.85%$263.11M2026-08-14
Citadel Advisors LLC▲ Buy2,921,1032.64%$243.97M2026-09-02
Geode Capital Management, LLC▼ Sell2,729,0302.47%$227.54M2026-08-12
Morgan Stanley▲ Buy2,100,8191.90%$175.46M2026-08-13
Norges Bank▲ Buy1,237,8321.12%$103.38M2026-08-12
Bank of America Corp▼ Sell1,212,4771.10%$101.27M2026-08-14
Goldman Sachs Group Inc▲ Buy1,174,2161.06%$98.07M2026-08-14
Northern Trust Corp▼ Sell964,4240.87%$80.55M2026-08-13
Balyasny Asset Management L.P.▲ Buy232,3020.21%$19.40M2026-08-14
Man Group plc▼ Sell95,4900.09%$7.98M2026-08-14
Neuberger Berman Group LLC▼ Sell81,5010.07%$6.81M2026-08-13
AllianceBernstein L.P.▼ Sell91,1730.08%$6.72M2026-08-14
Wells Fargo & Company▲ Buy76,0850.07%$6.35M2026-08-14
Citigroup Inc▲ Buy75,6670.07%$6.32M2026-08-03
Squarepoint Ops LLC▲ Buy64,2850.06%$5.37M2026-08-14
Bridgewater Associates, LP▲ Buy58,9930.05%$4.93M2026-08-14
Prudential Financial Inc▲ Buy50,3570.05%$4.21M2026-08-12
Janus Henderson Group plc▼ Sell49,1660.04%$3.62M2026-05-18
Marshall Wace, LLP▼ Sell37,5500.03%$3.14M2026-08-13
Point72 Asset Management, L.P.▼ Sell37,4020.03%$3.12M2026-08-14
Q2 2026 flow:6.07M sh bought ($506.67M)2.82M sh sold ($235.58M)net +3.24M sh (+$271.09M)
Congressional Trading Activity
6 disclosed trades · ~$72.5K est. traded value · 3 buys, 3 sells
MemberChamberStateTypeAmountTradedFiled
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-04-082025-05-08
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-04-012025-05-14
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-03-312025-04-07
Susan M. CollinsSenateME▼ Sell$15K - $50K2022-01-062022-02-17
Susan M. CollinsSenateME▲ Buy$1K - $15K2014-11-102014-12-01
Susan M. CollinsSenateME▲ Buy$1K - $15K2014-07-232015-07-20